Interactions between IL-15 and TGF-beta signalling pathways reveal novel therapeutic strategies to boost anti-cancer immunity

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1140406

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

This project will determine if new immune inhibitory checkpoints can be synergistically targeted with BRAFV600E inhibition to reactivate and allow NK cells to maximise their anti-tumour immune functions and prevent cancer spread. It is a completely novel approach that will allow for the more rational design of melanoma treatments that targets NK cells following surgery and local radiotherapy and/or chemotherapy.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $444,425.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Tumour Immunology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer immunology | cancer immunotherapy | cytokine signalling | mass spectrometry | transforming growth factor beta (TGF-beta)

Related Links